Complement component C5 iRNA compositions and methods of use thereof

US11162098B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Kevin Fitzgerald · Brookline, US
• James Butler · Lynnfield, US
• Brian Bettencourt · Groton, US
• Anna Borodovsky · Cambridge, US
• Satyanarayana Kuchimanchi · Cambridge, US
• Klaus Charisse · Acton, US
• Muthiah Manoharan · Carlsbad, US
• Martin Maier · Cambridge, US
• Kallanthottathil G. Rajeev · Wayland, US
• Donald C. Foster · Lake Forest Park, US

Key dates

• Filing date: May 7, 2019
• Grant date: Nov 2, 2021
• Expiry date: May 7, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.